Projects

Field friendly biometry to ease cohort studies in resource-limited settings: application to the Test and Treat for onchocerciasis project in Central Cameroon

Can a biometric recognition system, in the context of “Test and Treat”, facilitate individual follow-up by linking participant data at different time-points?

Countries: Cameroon
Diseases: Loiasis | Onchocerciasis

Processing Ov16 ELISA for Oncho Elimination Mapping

Would the same programmatic decisions for Oncho Elimination Mapping be made based off of the Ov16 rapid diagnostic test results as compared to the Ov16 SD ELISA results?

Countries: Kenya | Malawi | Burundi
Diseases: Onchocerciasis

Lymphatic Filariasis Positive-Case Follow-up After TAS 2 in Haiti

To identify the sampling strategy for positive case follow-up after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of ongoing transmission, while saving program resources.

Countries: Haiti

Understanding areas of increased trachoma risk (hotspots) through the implementation of a post validation trachoma surveillance strategy

To determine if there is evidence of on-going or recent transmission in the “hotspot” communities of increased risk two years after they were identified during the pre-validation surveys (clinical, antibody and infection data).

Countries: Ghana
Diseases: Trachoma

ClearTrachoma: Evaluation of a novel molecular rapid diagnostic device for the detection of Chlamydia trachomatis in trachoma-endemic areas

The primary aim of this study is a first evaluation (384 samples) of the DjinniChip in ocular clinical samples in a trachoma-endemic region in-country, but initially in the controlled environment of a research laboratory setting. The second aim is to determine the DjinniChips resilience and usability by evaluating its performance with a concentration series of positive control swabs in various environmental conditions (hot, dry, dusty, humid).

Countries: Tanzania
Diseases: Trachoma

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Samoa

  • What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of lymphatic filariasis (LF) has been reduced so that triple drug therapy with ivermectin, diethylcarbamazine, and albendazoe (IDA) can be stopped with little risk of resurgence of transmission?
  • To develop an M&E strategy that enables Samoa’s LF elimination program to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission
  • What is the effectiveness of appropriately dosed IDA in clearing Mf from Mf positive people who (i) reported taking IDA in August 2018, and (ii) did not report recently taking IDA?

 

Countries: Samoa

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Kenya

  • What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of lymphatic filariasis has been reduced so that triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) can be stopped with little risk of resurgence of transmission?
  • Can the use of a tailored social mobilization package be used to strengthen community and health system participation and achieve >80% coverage for IDA in Kenya?
Countries: Kenya

Does infection data add evidence to understanding of trachoma prevalence in low endemic areas?

To investigate the utility of an antibody test as a tool for surveillance during the elimination phase of trachoma programmes

Countries: Tanzania
Diseases: Trachoma

Pages